Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY B AUFFENBERG

Allopathic & Osteopathic Physicians Urology

NPI
1396977328
CMS profile
545463
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,472.24

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,472.24 53

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY B AUFFENBERG

NPI 1396977328 · CMS profile ID 545463

Allopathic & Osteopathic Physicians / Urology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396977328?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY B AUFFENBERG, NPI 1396977328, CMS profile ID 545463. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396977328?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GREGORY B AUFFENBERG, NPI 1396977328, CMS profile ID 545463. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396977328?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GREGORY B AUFFENBERG, NPI 1396977328, CMS profile ID 545463, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1396977328?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $1,472.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $20.9201/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048488205 CMS
Astellas Pharma US Inc $14.1701/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033873543 CMS
Verity Pharmaceuticals Inc. $16.1601/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019427053 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.72 1
PY2021 $33.78 2
PY2022 $607.17 33
PY2023 $1,472.24 53
PY2024 $1,077.68 42
PY2025 $907.12 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,700.00 1
PY2025 Principal investigator $248,578.49 51
PY2024 Principal investigator $190,278.42 38
PY2023 Principal investigator $25,155.11 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $8,817.00 12/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175432447
Principal investigator 1 Sumitomo Pharma America, Inc. $215.00 12/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657689
Principal investigator 1 Sumitomo Pharma America, Inc. $215.00 12/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657695
Principal investigator 1 Sumitomo Pharma America, Inc. $215.00 12/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657699
Principal investigator 1 Sumitomo Pharma America, Inc. $215.00 12/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657704
Principal investigator 1 Sumitomo Pharma America, Inc. $710.00 12/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657708
Principal investigator 1 Janssen Research & Development, LLC $23,917.00 12/18/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175432500
Principal investigator 1 Janssen Research & Development, LLC $160.00 12/15/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175432441
Principal investigator 1 Janssen Research & Development, LLC $160.00 11/21/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175432393
Principal investigator 1 Janssen Research & Development, LLC $975.00 11/07/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175432487
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654703
Principal investigator 1 Sumitomo Pharma America, Inc. $900.60 11/05/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654742
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654746
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654754
Principal investigator 1 Sumitomo Pharma America, Inc. $225.00 11/05/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654763
Principal investigator 1 Sumitomo Pharma America, Inc. $4,503.00 11/05/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654849
Principal investigator 1 Janssen Research & Development, LLC $3,339.00 11/03/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175432493
Principal investigator 1 Janssen Research & Development, LLC $3,802.00 10/10/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175432388
Principal investigator 1 Janssen Research & Development, LLC $4,543.00 10/03/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175432539
Principal investigator 1 Janssen Research & Development, LLC $1,196.69 09/19/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432431
Principal investigator 1 Janssen Research & Development, LLC $975.00 09/08/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432360
Principal investigator 1 Janssen Research & Development, LLC $2,302.00 09/08/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432365
Principal investigator 1 Janssen Research & Development, LLC $975.00 08/11/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432517
Principal investigator 1 Janssen Research & Development, LLC $160.00 08/07/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432436
Principal investigator 1 Janssen Research & Development, LLC $14,218.00 08/04/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432505
Principal investigator 1 Janssen Research & Development, LLC $21,430.00 07/28/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432377
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 07/09/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640322
Principal investigator 1 Janssen Research & Development, LLC $3,568.00 07/04/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432372
Recipient Dendreon Pharmaceuticals LLC $11,700.00 06/30/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891291
Principal investigator 2 Dendreon Pharmaceuticals LLC $11,700.00 06/30/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
ProvONE No dispute reported 06/30/2026 1247892254
Principal investigator 1 Janssen Research & Development, LLC $25,948.00 06/30/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432419
Principal investigator 1 Janssen Research & Development, LLC $2,699.00 06/23/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432475
Principal investigator 1 Sumitomo Pharma America, Inc. $2,920.00 06/18/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636432
Principal investigator 1 Janssen Research & Development, LLC $1,055.00 06/02/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175432534
Principal investigator 1 Janssen Research & Development, LLC $2,699.00 05/22/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432413
Principal investigator 1 Janssen Research & Development, LLC $23,961.00 05/19/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432463
Principal investigator 1 Janssen Research & Development, LLC $4,604.00 05/19/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432529
Principal investigator 1 Janssen Research & Development, LLC $4,060.00 05/12/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432408
Principal investigator 1 Janssen Research & Development, LLC $2,859.00 05/08/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432454
Principal investigator 1 Sumitomo Pharma America, Inc. $450.00 05/07/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634226
Principal investigator 1 Sumitomo Pharma America, Inc. $900.60 05/07/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634230
Principal investigator 1 Janssen Research & Development, LLC $16,437.00 04/25/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432402
Principal investigator 1 Sumitomo Pharma America, Inc. $3,602.40 04/09/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632741
Principal investigator 1 Sumitomo Pharma America, Inc. $4,593.00 04/09/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632745
Principal investigator 1 Sumitomo Pharma America, Inc. $1,801.20 04/09/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632750
Principal investigator 1 Sumitomo Pharma America, Inc. $1,350.00 04/09/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632755
Principal investigator 1 Janssen Research & Development, LLC $4,959.00 04/07/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432469
Principal investigator 1 Janssen Research & Development, LLC $12,763.00 03/28/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432424
Principal investigator 1 Janssen Research & Development, LLC $8,725.00 02/28/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432383
Principal investigator 1 Janssen Research & Development, LLC $650.00 02/24/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432511
Principal investigator 1 Janssen Research & Development, LLC $9,137.00 02/13/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175432481
Principal investigator 1 Janssen Research & Development, LLC $2,849.00 01/13/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST L OUIS LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175432524